Podcast: Play in new window | Download
Subscribe: Google Podcasts | RSS
Dr. Debra Kimless is the CMO of Pure Green Pharmaceuticals, where she oversees clinical medical testing, patient and physician educational programs, and medical product development. Deb and her team recently published an open-label clinical trial for treating diabetic neuropathic pain with a water-soluble CBD tablet.
In our conversation we discuss:
- Results from her clinical trial for treating diabetic neuropathic pain with CBD
- What makes diabetic neuropathic pain a good candidate for cannabinoid therapies
- Comparing the adverse effects of standard DNP treatments to CBD
- The advantages of delivering cannabinoids via a water-soluble tablet
- Why there are not more clinical studies into cannabinoid therapies
- Tools consumers can use to identify proper clinical trials
Thanks to This Episode’s Sponsor: Pure Green Pharmaceuticals
Pure Green Pharmaceuticals manufactures the finest medical products, using selected cannabinoid molecules as primary ingredients. Their goal is to relieve human and animal suffering through the use of purified cannabis.
Learn more at pgpharma.co
Additional Resources